Identification of APC Mutation as a Potential Predictor for Immunotherapy in Colorectal Cancer

Table 1

Clinical characteristics and biomarkers of CRC patients.

	Total (n = 238)	APC-MT group (n = 175)	APC-WT group (n = 63)	value
Age	59 (26–89)	61 (52–68)	59 (49–66)	0.189
Gender
Female	99	72	27	0.882
Male	139	103	36
Stage^#
I–III	64	45	19	0.614
IV	112	87	29
Type^#
Colon	113	82	31	0.186
Rectum	89	72	17
MSI
MSI-H	15	9	6	0.223
MSI-L	223	166	57
HLA LOH
Yes	39	32	7	0.235
No	199	143	56
TMB	6.69 (4.69–8.71)	6.7 (4.69–8.73)	5.36 (3.59–7.64)	0.022
TNB	2.62 (1.34–4.69)	2.68 (1.34–4.02)	2.55 (0.67–4.70)	0.766

TMB, tumor mutation burden; Mut/Mb, mutations per megabase; TNB, tumor neoantigen burden; Neo/Mb, neoantigens per megabase; HLA, human leukocyte antigen; LOH, loss of heterogeneity. values <0.05. ^#Some data were missing.